Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status approved; investigational
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 0069-0145; 54893-0032; 68554-0088; 63539-026; 82920-028; 0069-0151; 65344-0033; 63539-044; 54893-0043
UNII C9LVQ0YUXG
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.000448%
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.0110.000560%
Urinary tract disorder20.08.01.001--Not Available
Venous thrombosis24.01.01.0080.000112%Not Available
Vomiting07.01.07.0030.015424%
Weight decreased13.15.01.005--
White blood cell count decreased13.01.06.012--
Mobility decreased15.03.05.023; 08.01.03.030; 17.02.05.0180.001119%Not Available
Musculoskeletal disorder15.03.05.025--Not Available
Poor venous access24.03.02.017--Not Available
Hypoacusis04.02.01.0060.002183%
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.0130.000627%Not Available
Performance status decreased08.01.03.0420.000246%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.005082%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000224%
Scar pain23.03.03.0600.000437%Not Available
Weight fluctuation14.03.02.002--Not Available
Chapped lips07.05.01.0040.000929%Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.0050.000112%Not Available
Food aversion19.09.03.002; 14.03.02.029--Not Available
Lip blister23.03.01.016; 07.05.01.0070.000571%Not Available
General physical health deterioration08.01.03.0180.002910%Not Available
Left ventricular dysfunction02.04.02.0110.000168%
Tumour haemorrhage24.07.01.028; 16.32.03.0080.000280%
Balance disorder08.01.03.081; 17.02.02.0070.002026%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000660%Not Available
Metastatic renal cell carcinoma20.01.04.005; 16.08.02.0030.007578%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000492%
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 17 Pages